Abstract：
:Bulimia nervosa is an eating disorder characterised by recurrent episodes of binge eating and associated efforts to purge the ingested calories through self-induced vomiting, laxative or diuretic abuse, fasting or intensive exercise. The aetiopathogenesis and pathophysiology of the disorder are currently unclear. Biological bases have been proposed repeatedly, based on several lines of evidence: hunger, satiety and food choice are regulated by neurotransmitters and neuropeptides, and impairment of eating habits may be related to alterations in the secretion of these chemicals; genetic studies suggest that these neurotransmitter systems are dysfunctional in individuals with bulimia nervosa; and the frequent comorbidity of bulimia nervosa with major depressive and obsessive-compulsive disorders, conditions in which multiple alterations of brain biochemical functions have been demonstrated. Data in the literature suggest that levels of noradrenaline (norepinephrine) and serotonin (5-hydroxytryptamine; 5-HT) are lower in individuals with bulimia nervosa than in healthy controls. Levels of dopamine are similar to, or lower than, those in controls. After remission of the disorder, noradrenergic function returns to that seen in controls, whereas dopaminergic and serotonergic function rebound to levels higher than in controls. Among the neuropeptides, alterations in the levels of neuropeptide Y, peptide YY, beta-endorphin, corticotrophin-releasing hormone, somatostatin, cholecystokinin and vasopressin have been found in the symptomatic phase of bulimia nervosa, with a return to levels seen in controls after remission. Pharmacological treatment of bulimia nervosa that is directed at correction of the neurochemical alterations observed is difficult because of the complexity of the impairments. However, such treatment is necessary and should be continued long after symptomatic remission to ensure reinstitution of cerebral biochemical homeostasis.
journal_name
CNS Drugsjournal_title
CNS drugsauthors
Brambilla Fdoi
10.2165/00023210-200115020-00004subject
Has Abstractpub_date
2001-01-01 00:00:00pages
119-36issue
2eissn
1172-7047issn
1179-1934journal_volume
15pub_type
杂志文章,评审相关文献
CNS DRUGS文献大全abstract：:Anticonvulsant hypersensitivity syndrome (AHS) is a rare, but potentially fatal, adverse reaction that occurs in patients, including children, who are treated with anticonvulsants. During metabolism of the anticonvulsant, toxic arene-oxide compounds are produced. AHS is associated with both cutaneous and systemic symp...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200216030-00006
更新日期：2002-01-01 00:00:00
abstract：:Infections are common in people with dementia, and antibiotic use is widespread, albeit highly variable, across healthcare settings and countries. The few studies conducted to date that consider the appropriateness of antibiotic prescribing specifically for people with dementia focus on people with advanced dementia a...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.1007/s40263-017-0427-y
更新日期：2017-06-01 00:00:00
abstract：:Varenicline (Chantix, Champix) is an orally administered alpha4beta2 nicotinic acetylcholine receptor partial agonist that is indicated as an aid to smoking cessation. Varenicline was an effective aid to smoking cessation and was generally well tolerated in clinical trials, although more data are needed regarding the ...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/11204710-000000000-00000
更新日期：2010-09-01 00:00:00
abstract：:Hashimoto's encephalopathy is a term used to describe an encephalopathy of presumed autoimmune origin characterised by high titres of antithyroid peroxidase antibodies. In a similar fashion to autoimmune thyroid disease, Hashimoto's encephalopathy is more common in women than in men. It has been reported in paediatric...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200721100-00002
更新日期：2007-01-01 00:00:00
abstract：:Alcoholic patients suffer from harmful allostatic neuroplastic changes in the brain causing an acute withdrawal syndrome upon cessation of drinking followed by a protracted abstinence syndrome and an increased risk of relapse to heavy drinking. Benzodiazepines have long been the treatment of choice for detoxifying pat...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-015-0240-4
更新日期：2015-04-01 00:00:00
abstract：:Postherpetic neuralgia, which occurs most typically in older persons, is one of the most common and serious complications of herpes zoster (or shingles). It is a chronic neuropathic pain syndrome and remains one of the most difficult pain disorders to treat. Known beneficial agents include antidepressants, antiepilept...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200317110-00001
更新日期：2003-01-01 00:00:00
abstract：:Spinal muscular atrophy (SMA) is a rare autosomal recessive neuromuscular disorder most commonly caused by a deletion or mutation in the survival motor neuron 1 (SMN1) gene, which leads to insufficient levels of survival motor neuron (SMN) protein. In such patients, SMN protein production relies on the SMN2 gene. Nusi...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-018-0545-1
更新日期：2018-07-01 00:00:00
abstract：:Major depressive disorder (MDD) is a chronic, recurrent mental disease that causes serious disability. Because currently available antidepressants have limited efficacy with respect to response and remission in patients with MDD, clinicians must choose the best available treatment interventions for patients who do not...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-012-0032-z
更新日期：2013-05-01 00:00:00
abstract：:Lacosamide (Vimpat(®)) is a functionalized amino acid available orally (as a syrup or tablet) and as an intravenous infusion. It is believed to exert its antiepileptic effect by selectively enhancing the slow inactivation of voltage-gated sodium channels. Lacosamide is approved in several countries worldwide as an adj...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-013-0123-5
更新日期：2013-12-01 00:00:00
abstract：:Multiple stimulant and non-stimulant medications are approved for the treatment of attention-deficit/hyperactivity disorder (ADHD), one of the most prevalent childhood neurodevelopmental disorders. Choosing among the available agents and determining the most effective ADHD medication for a given child can be a time-co...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-020-00702-y
更新日期：2020-04-01 00:00:00
abstract：:It is difficult to determine the relative efficacy of atypical antipsychotics for the treatment of schizophrenia, based on the available literature. The purpose of this article is to review and compare the efficacy of two atypical antipsychotics: olanzapine and ziprasidone.This review focused on randomised trials in w...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200519060-00003
更新日期：2005-01-01 00:00:00
abstract：:Insomnia, an inability to initiate or maintain sleep, affects approximately one-third of the American population. Conventional benzodiazepines, such as triazolam and midazolam, were the treatment of choice for short-term insomnia for many years but are associated with adverse effects such as rebound insomnia, withdraw...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200317070-00004
更新日期：2003-01-01 00:00:00
abstract：:The pervasive and devastating nature of substance use disorders underlies the need for the continued development of novel pharmacotherapies. We now know that glia play a much greater role in neuronal processes than once believed. The various types of glial cells (e.g., astrocytes, microglial, oligodendrocytes) partic...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.1007/s40263-020-00721-9
更新日期：2020-07-01 00:00:00
abstract：:Oral blonanserin (Lonasen) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. It is effective in the treatment of patients with schizophrenia, providing short- and long-term efficacy against both the positive and negative symptoms of the disorder in several randomiz...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/11202620-000000000-00000
更新日期：2010-01-01 00:00:00
abstract：:Teriflunomide is a once-daily oral agent that has been licensed in the EU since August 2013 for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS). More recently (September 2014), the EU summary of product characteristics (SmPC) was updated to include data from patients with a first cli...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-015-0299-y
更新日期：2016-01-01 00:00:00
abstract：:In this article, we review the evidence that tocopherol (vitamin E) may have a role to play in the prevention and treatment of Alzheimer's disease and other neurological diseases. The theoretical rationale for the effectiveness of tocopherol as treatment and/or prevention of Alzheimer's disease is based on its antioxi...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200418120-00005
更新日期：2004-01-01 00:00:00
abstract：:Treatment of pediatric migraine remains an unmet medical need. There continues to be a paucity of pediatric randomized controlled trials for the treatment of migraine, both in the acute and preventive settings. Pediatric studies are often complicated by high placebo-response rates and much of our current practice is b...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-016-0375-y
更新日期：2016-09-01 00:00:00
abstract：INTRODUCTION AND OBJECTIVE:Haemorrheological parameters and endothelial function are known to be altered in vascular diseases, including stroke. Treatment with HMG-CoA reductase inhibitors ('statins') improves cerebrovascular (and cardiovascular) morbidity and mortality in patients with atherosclerosis; the beneficial ...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.2165/00023210-200418030-00003
更新日期：2004-01-01 00:00:00
abstract：:Subacute sclerosing panencephalitis (SSPE) is a chronic progressive, usually fatal disease of uncertain pathogenesis that is associated with the presence of mutant measles virus in the CNS. The diagnosis is based on clinical criteria and an elevated titre of measles antibodies in the CSF. Electroencephalography, imagi...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.2165/00023210-199707020-00003
更新日期：1997-02-01 00:00:00
abstract：:Satisfactory management of Parkinson's disease is a challenge that requires a tailored approach for each individual. In the advanced phase of the disease, patients may experience motor complications despite optimized pharmacological therapy. Apomorphine, a short-acting D1- and D2-like receptor agonist, is the only dru...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-019-00661-z
更新日期：2019-09-01 00:00:00
abstract：:Smokeless tobacco (SLT) is used in a variety of forms throughout the world. Long-term SLT use is associated with adverse health consequences. Effective pharmacotherapies are needed to treat SLT users who want to achieve tobacco abstinence. In the current review, we discuss the pharmacological interventions identified ...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/11598450-000000000-00000
更新日期：2012-01-01 00:00:00
abstract：:Symptoms of anxiety and depression often appear together in patients, either as 2 discrete disorders, such as major depressive disorder and panic disorder, or as a combination of symptoms not meeting criteria for specific disorders. The social, economic, occupational and medical costs of such comorbid anxiety and depr...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.2165/00023210-199809040-00003
更新日期：1998-04-01 00:00:00
abstract：:The coronavirus 2019 (COVID-19) pandemic is expected to linger. Decisions regarding initiation or continuation of disease-modifying therapy for multiple sclerosis have to consider the potential relevance to the pandemic. Understanding the mechanism of action and the possible idiosyncratic effects of each therapeutic a...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-020-00756-y
更新日期：2020-09-01 00:00:00
abstract：:Loxapine is a well-established, first-generation antipsychotic agent. Loxapine inhalation powder (Adasuve(®)) was recently approved in the USA and the EU for use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. Inhaled loxapine is delivered by a hand-held, single-dose, single-use...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-013-0075-9
更新日期：2013-06-01 00:00:00
abstract：:Spinal cord injury (SCI) has a number of severe and disabling consequences, including chronic pain, and around 40% of patients develop persistent neuropathic pain. Pain following SCI has a detrimental impact on the patient's quality of life and is a major specific healthcare problem in its own right. Thus far, there i...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200822060-00002
更新日期：2008-01-01 00:00:00
abstract：:Premature mortality due to cardiovascular disease in those with schizophrenia is the largest lifespan disparity in the US and is growing; adults in the US with schizophrenia die, on average, 28 years earlier than those in the general population. The rate of smoking prevalence among individuals with schizophrenia is es...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-017-0438-8
更新日期：2017-06-01 00:00:00
abstract：BACKGROUND:No head-to-head clinical trials have been published comparing guanfacine extended release (GXR) and atomoxetine (ATX): two nonstimulants approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). However, other study designs or methods could be used to indirectly compare these two medicat...
journal_title：CNS drugs
pub_type： 杂志文章
doi：10.1007/s40263-013-0102-x
更新日期：2013-11-01 00:00:00
abstract：:All current antipsychotic drugs block dopamine (DA) receptors, but the nature of the DA dysfunction in schizophrenia has not been clear. However, consistent evidence now shows that presynaptic dopaminergic function is altered in schizophrenia, specifically in terms of increased DA synthesis capacity, baseline synaptic...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.1007/s40263-014-0177-z
更新日期：2014-07-01 00:00:00
abstract：:New formulations of stimulant medications for the treatment of attention-deficit hyperactivity disorder (ADHD) have been an important focus for pharmaceutical industry research and development over the past decade. In this article, we review and assess the therapeutic potential of five new stimulant formulations (one ...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200418140-00005
更新日期：2004-01-01 00:00:00
abstract：:In recent years, several new antiepileptic drugs (AEDs) have been licensed: felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, vigabatrin and zonisamide. These drugs have proven efficacy as add-on therapy in patients with difficult-to-treat partial epilepsy, as 20-50% of patients ...
journal_title：CNS drugs
pub_type： 杂志文章,评审
doi：10.2165/00023210-200317060-00003
更新日期：2003-01-01 00:00:00
